CIAS
SRPT icon

Capital Investment Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Capital Investment Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100
Closed -$8K – 1153
2019
Q3 		$8K Hold
100
– – ﹤0.01% 1044
2019
Q2 		$14K Buy
+100
New +$12.2K ﹤0.01% 883

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Capital Investment Advisory Services's SRPT Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 100 shares — an estimated $8K sold.

Capital Investment Advisory Services first reported a position in SRPT in Q2 2019 and held it in 2 quarters. The position peaked at $14K in Q2 2019. 389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 100 Sarepta Therapeutics shares in Q4 2019, an estimated $8K.
  • Capital Investment Advisory Services first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 2 quarters.
  • Capital Investment Advisory Services's Sarepta Therapeutics position peaked at $14K in Q2 2019.
  • 389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.